ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
cainy
|
261 |
64K |
14 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
261
|
64K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
cainy
|
77 |
19K |
7 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
77
|
19K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
16 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.3K
|
326K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
58 |
17K |
21 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
58
|
17K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
cainy
|
282 |
74K |
6 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
282
|
74K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
cainy
|
282 |
74K |
13 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
282
|
74K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
cainy
|
126 |
31K |
10 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
126
|
31K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
cainy
|
126 |
31K |
22 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
126
|
31K
|
22
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
cainy
|
196 |
36K |
4 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
196
|
36K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
cainy
|
196 |
36K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
196
|
36K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
cainy
|
63 |
16K |
6 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
63
|
16K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
cainy
|
63 |
16K |
20 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
63
|
16K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
17 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
1.3K
|
326K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
15 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
15
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
26 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Presentation - Phase 1 Top-Line Results
|
|
cainy
|
34 |
10K |
10 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
34
|
10K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
cainy
|
209 |
49K |
7 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
49K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
cainy
|
209 |
49K |
11 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
49K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
114 |
33K |
8 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
114
|
33K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
114 |
33K |
7 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
114
|
33K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
19 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
19 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
11 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
9 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
cainy
|
1.3K |
326K |
9 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
1.3K
|
326K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
cainy
|
197 |
51K |
22 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
197
|
51K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
cainy
|
58 |
15K |
16 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
58
|
15K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
cainy
|
197 |
51K |
16 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
197
|
51K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
cainy
|
282 |
74K |
21 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
282
|
74K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Grants PharmAust Pre-IND Meeting
|
|
cainy
|
61 |
17K |
6 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
61
|
17K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
cainy
|
430 |
107K |
15 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
430
|
107K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
cainy
|
430 |
107K |
14 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
430
|
107K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Launches Interactive Investor Hub
|
|
cainy
|
16 |
3.3K |
2 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
16
|
3.3K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
87 |
18K |
6 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
87
|
18K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
87 |
18K |
3 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
87
|
18K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
87 |
18K |
11 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
87
|
18K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Raises $3.5 Million at a Premium
|
|
cainy
|
60 |
14K |
16 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
60
|
14K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Raises $3.5 Million at a Premium
|
|
cainy
|
60 |
14K |
8 |
13/12/23 |
13/12/23 |
ASX - By Stock
|
60
|
14K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
cainy
|
355 |
68K |
1 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
355
|
68K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
cainy
|
355 |
68K |
8 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
355
|
68K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
cainy
|
76 |
13K |
7 |
16/11/23 |
16/11/23 |
ASX - By Stock
|
76
|
13K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
cainy
|
76 |
13K |
7 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
76
|
13K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
cainy
|
79 |
16K |
8 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
79
|
16K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
cainy
|
79 |
16K |
7 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
79
|
16K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final MND Patient in Cohort 4 Successfully Completes Dosing
|
|
cainy
|
125 |
24K |
4 |
13/10/23 |
13/10/23 |
ASX - By Stock
|
125
|
24K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
cainy
|
106 |
21K |
4 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
106
|
21K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
cainy
|
380 |
83K |
5 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
380
|
83K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
cainy
|
380 |
83K |
10 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
380
|
83K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notification of expiry of quoted options
|
|
cainy
|
43 |
9.1K |
9 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
43
|
9.1K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, The New Dawn, September , Optober 2023
|
|
cainy
|
132 |
32K |
5 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
132
|
32K
|
5
|
|